For example, PARP inhibitors have been suggested for use in germline BRCA mutation-associated breast cancer (gBRCAm-BC), and checkpoint inhibitor atezolizumab combined with nab-paclitaxel in programmed cell death-ligand 1-positive (PD-L1+) advanced TNBC [37,38]. The gene discussed is CD274; the disease is breast carcinoma.